Moreover, a highly successful trial of the TNF-targeting antibody golimumab showed improvement in C-peptide responses and clinical parameters when it was administered to participants aged 6–21 years with stage 3 T1D for ≤52 weeks158. This evidence concerns the gene TNF and type 1 diabetes mellitus.